A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
Clinical trial NCT06054555 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06054555
- Sponsor
- Amgen
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-02
- Primary completion
- 2028-01-25
- Enrollment
- 633
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.